Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
4400 | 1792 | 42.7 | 78% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
5 | 4 | CHEMISTRY, ORGANIC//CHEMISTRY, INORGANIC & NUCLEAR//CHEMISTRY, MULTIDISCIPLINARY | 1745167 |
346 | 3 | CARDIOTOXICITY//ANTHRACYCLINES//CAMPTOTHECIN | 36072 |
2227 | 2 | CARDIOTOXICITY//ANTHRACYCLINES//DOXORUBICIN | 4791 |
4400 | 1 | CARDIOTOXICITY//ANTHRACYCLINES//CARDIO ONCOLOGY | 1792 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | CARDIOTOXICITY | authKW | 2568113 | 30% | 28% | 545 |
2 | ANTHRACYCLINES | authKW | 1208537 | 20% | 20% | 352 |
3 | CARDIO ONCOLOGY | authKW | 424619 | 2% | 69% | 36 |
4 | ANTHRACYCLINE CARDIOTOXICITY | authKW | 257503 | 1% | 66% | 23 |
5 | TRASTUZUMAB | authKW | 190684 | 8% | 8% | 145 |
6 | ANTHRACYCLINE INDUCED CARDIOTOXICITY | authKW | 125459 | 1% | 82% | 9 |
7 | CARDIAC TOXICITY | authKW | 112122 | 2% | 15% | 44 |
8 | UOC MAGNET ONANCE IMAGING | address | 87623 | 0% | 86% | 6 |
9 | DEXRAZOXANE | authKW | 73788 | 1% | 17% | 26 |
10 | ANTHRACYCLINES ADVERSE EFFECTS | authKW | 70990 | 0% | 83% | 5 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 10418 | 40% | 0% | 715 |
2 | Cardiac & Cardiovascular System | 9172 | 29% | 0% | 513 |
3 | Hematology | 2539 | 12% | 0% | 217 |
4 | Pediatrics | 1421 | 11% | 0% | 189 |
5 | Transplantation | 656 | 4% | 0% | 78 |
6 | Medicine, General & Internal | 352 | 8% | 0% | 145 |
7 | Pharmacology & Pharmacy | 128 | 8% | 0% | 137 |
8 | Peripheral Vascular Diseases | 121 | 3% | 0% | 57 |
9 | Radiology, Nuclear Medicine & Medical Imaging | 84 | 4% | 0% | 71 |
10 | Toxicology | 58 | 3% | 0% | 45 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | UOC MAGNET ONANCE IMAGING | 87623 | 0% | 86% | 6 |
2 | TED ROGERS PROGRAM CARDIOTOX PREVENT | 68152 | 0% | 100% | 4 |
3 | CARDIONCOL UNIT | 61332 | 0% | 60% | 6 |
4 | UOC CARDIOL INTENS UNIT | 54520 | 0% | 80% | 4 |
5 | MED SCI MARIO A U | 54237 | 1% | 29% | 11 |
6 | CARDIOONCOL PROGRAM | 36073 | 0% | 35% | 6 |
7 | CARDIOL PULMONOL CRIT CARE MED | 34076 | 0% | 100% | 2 |
8 | INTEGRATED CANC GHENT | 34076 | 0% | 100% | 2 |
9 | INTERNAL MED ONCOL CLIN | 34076 | 0% | 100% | 2 |
10 | UVA HEMATOL ONCOL | 34076 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PEDIATRIC BLOOD & CANCER | 8990 | 3% | 1% | 49 |
2 | JOURNAL OF CLINICAL ONCOLOGY | 7325 | 5% | 1% | 84 |
3 | CARDIOVASCULAR TOXICOLOGY | 6880 | 1% | 3% | 13 |
4 | PEDIATRIC HEMATOLOGY AND ONCOLOGY | 3665 | 1% | 1% | 21 |
5 | BONE MARROW TRANSPLANTATION | 3354 | 2% | 0% | 42 |
6 | HEART FAILURE CLINICS | 3299 | 0% | 2% | 8 |
7 | MEDICAL AND PEDIATRIC ONCOLOGY | 3263 | 1% | 1% | 22 |
8 | JOURNAL OF CARDIOVASCULAR MEDICINE | 3258 | 1% | 1% | 18 |
9 | ONCOLOGIST | 3048 | 1% | 1% | 20 |
10 | JOURNAL OF CARDIAC FAILURE | 2522 | 1% | 1% | 16 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CARDIOTOXICITY | 2568113 | 30% | 28% | 545 | Search CARDIOTOXICITY | Search CARDIOTOXICITY |
2 | ANTHRACYCLINES | 1208537 | 20% | 20% | 352 | Search ANTHRACYCLINES | Search ANTHRACYCLINES |
3 | CARDIO ONCOLOGY | 424619 | 2% | 69% | 36 | Search CARDIO+ONCOLOGY | Search CARDIO+ONCOLOGY |
4 | ANTHRACYCLINE CARDIOTOXICITY | 257503 | 1% | 66% | 23 | Search ANTHRACYCLINE+CARDIOTOXICITY | Search ANTHRACYCLINE+CARDIOTOXICITY |
5 | TRASTUZUMAB | 190684 | 8% | 8% | 145 | Search TRASTUZUMAB | Search TRASTUZUMAB |
6 | ANTHRACYCLINE INDUCED CARDIOTOXICITY | 125459 | 1% | 82% | 9 | Search ANTHRACYCLINE+INDUCED+CARDIOTOXICITY | Search ANTHRACYCLINE+INDUCED+CARDIOTOXICITY |
7 | CARDIAC TOXICITY | 112122 | 2% | 15% | 44 | Search CARDIAC+TOXICITY | Search CARDIAC+TOXICITY |
8 | DEXRAZOXANE | 73788 | 1% | 17% | 26 | Search DEXRAZOXANE | Search DEXRAZOXANE |
9 | ANTHRACYCLINES ADVERSE EFFECTS | 70990 | 0% | 83% | 5 | Search ANTHRACYCLINES+ADVERSE+EFFECTS | Search ANTHRACYCLINES+ADVERSE+EFFECTS |
10 | ANTHRACYCLINE CHEMOTHERAPY | 68148 | 0% | 67% | 6 | Search ANTHRACYCLINE+CHEMOTHERAPY | Search ANTHRACYCLINE+CHEMOTHERAPY |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | PLANA, JC , GALDERISI, M , BARAC, A , EWER, MS , KY, B , SCHERRER-CROSBIE, M , GANAME, J , SEBAG, IA , AGLER, DA , BADANO, LP , ET AL (2014) EXPERT CONSENSUS FOR MULTIMODALITY IMAGING EVALUATION OF ADULT PATIENTS DURING AND AFTER CANCER THERAPY: A REPORT FROM THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY AND THE EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING.JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY. VOL. 27. ISSUE 9. P. 911 -939 | 102 | 54% | 82 |
2 | CURIGLIANO, G , CARDINALE, D , DENT, S , CRISCITIELLO, C , ASEYEV, O , LENIHAN, D , CIPOLLA, CM , (2016) CARDIOTOXICITY OF ANTICANCER TREATMENTS: EPIDEMIOLOGY, DETECTION, AND MANAGEMENT.CA-A CANCER JOURNAL FOR CLINICIANS. VOL. 66. ISSUE 4. P. 310 -325 | 87 | 62% | 6 |
3 | PLANA, JC , GALDERISI, M , BARAC, A , EWER, MS , KY, B , SCHERRER-CROSBIE, M , GANAME, J , SEBAG, IA , AGLER, DA , BADANO, LP , ET AL (2014) EXPERT CONSENSUS FOR MULTIMODALITY IMAGING EVALUATION OF ADULT PATIENTS DURING AND AFTER CANCER THERAPY: A REPORT FROM THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY AND THE EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING.EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING. VOL. 15. ISSUE 10. P. 1063 -1093 | 102 | 54% | 51 |
4 | CHRISTENSON, ES , JAMES, T , AGRAWAL, V , PARK, BH , (2015) USE OF BIOMARKERS FOR THE ASSESSMENT OF CHEMOTHERAPY-INDUCED CARDIAC TOXICITY.CLINICAL BIOCHEMISTRY. VOL. 48. ISSUE 4-5. P. 223 -235 | 92 | 69% | 9 |
5 | ZAMORANO, JL , LANCELLOTTI, P , MUNOZ, D , ABOYANS, V , ASTEGGIANO, R , GALDERISI, M , HABIB, G , LENIHAN, DJ , LIP, GYH , LYON, AR , ET AL (2017) 2016 ESC POSITION PAPER ON CANCER TREATMENTS AND CARDIOVASCULAR TOXICITY DEVELOPED UNDER THE AUSPICES OF THE ESC COMMITTEE FOR PRACTICE GUIDELINES THE TASK FORCE FOR CANCER TREATMENTS AND CARDIOVASCULAR TOXICITY OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC).EUROPEAN JOURNAL OF HEART FAILURE. VOL. 19. ISSUE 1. P. 9 -42 | 107 | 39% | 1 |
6 | ZAMORANO, JL , LANCELLOTTI, P , MUNOZ, DR , ABOYANS, V , ASTEGGIANO, R , GALDERISI, M , HABIB, G , LENIHAN, DJ , LIP, GYH , LYON, AR , ET AL (2016) 2016 ESC POSITION PAPER ON CANCER TREATMENTS AND CARDIOVASCULAR TOXICITY DEVELOPED UNDER THE AUSPICES OF THE ESC COMMITTEE FOR PRACTICE GUIDELINES.EUROPEAN HEART JOURNAL. VOL. 37. ISSUE 36. P. 2768 -2801 | 108 | 39% | 4 |
7 | THAVENDIRANATHAN, P , POULIN, F , LIM, KD , PLANA, JC , WOO, A , MARWICK, TH , (2014) USE OF MYOCARDIAL STRAIN IMAGING BY ECHOCARDIOGRAPHY FOR THE EARLY DETECTION OF CARDIOTOXICITY IN PATIENTS DURING AND AFTER CANCER CHEMOTHERAPY.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. VOL. 63. ISSUE 25. P. 2751 -2768 | 42 | 75% | 98 |
8 | POULIN, F , THAVENDIRANATHAN, P , (2015) CARDIOTOXICITY DUE TO CHEMOTHERAPY: ROLE OF CARDIAC IMAGING.CURRENT CARDIOLOGY REPORTS. VOL. 17. ISSUE 3. P. - | 82 | 63% | 1 |
9 | BLOOM, MW , HAMO, CE , CARDINALE, D , KY, B , NOHRIA, A , BAER, L , SKOPICKI, H , LENIHAN, DJ , GHEORGHIADE, M , LYON, AR , ET AL (2016) CANCER THERAPY-RELATED CARDIAC DYSFUNCTION AND HEART FAILURE PART 1: DEFINITIONS, PATHOPHYSIOLOGY, RISK FACTORS, AND IMAGING.CIRCULATION-HEART FAILURE. VOL. 9. ISSUE 1. P. - | 53 | 67% | 6 |
10 | JONES, RL , SWANTON, C , EWER, MS , (2006) ANTHRACYCLINE CARDIOTOXICITY.EXPERT OPINION ON DRUG SAFETY. VOL. 5. ISSUE 6. P. 791-809 | 98 | 56% | 63 |
Classes with closest relation at Level 1 |